Related Experiment Video
Updated: Jun 10, 2026
Dynamic Multiparameter Platelet Function Assessment Using a Capacitive Biosensor
Published on: May 2, 2025
Evaluation of platelet function and pharmacological platelet inhibition in patients with myeloproliferative disorders
Christoph Robier1, Manfred Neubauer, Heinz Sternad
1Central Laboratory, Department of Internal Medicine, Hospital Barmherzige Brueder Graz-Eggenberg, Austria. christoph.robier@bbegg.at
Background:
The aim of this study was to describe platelet aggregation characteristics by multiple electrode aggregometry (MEA) and to evaluate MEA for its potential to detect platelet dysfunction and response to anti-aggregatory drugs in patients with myeloproliferative disorders (MPD).
Methods:
We compared the platelet response to arachidonic acid (ASPI test), adenosine diphosphate (ADP test) and thrombin receptor activating peptide (TRAP test) in hirudin-anticoagulated blood of 55 patients with polycythaemia vera and essential thrombocythaemia and 75 controls.
Results:
Comparing MPD patients and controls no statistically significant difference indicative of platelet dysfunction was found in MPD patients. Analysis of covariance revealed platelet- and leukocyte count as a significant influencing factor on MEA function. Furthermore we could demonstrate that ASA and clopidogrel treatment results in a statistically significant lower ASPI (Controls: p<0.0001, MPD: p<0.0001) and ADPtest value (MPD: p=0.00125) compared to untreated patients thereby validating the method for monitoring of anti-aggregatory therapy.
Conclusion:
In this study MEA was confirmed as a valid method for monitoring of ASA and clopidogrel treatment in patients with MPD and normal control subjects. The platelet and leukocyte count were identified as major influencing factors on MEA aggregation tests both in MPD patients and controls. No functional platelet abnormalities were detected in MPD patients.
Insights
Multiple electrode aggregometry (MEA) effectively monitors anti-platelet drug response in myeloproliferative disorder (MPD) patients. Platelet and leukocyte counts significantly influence MEA results, but MPD patients showed no inherent platelet dysfunction.
Area of Science:
- Hematology
- Clinical Pathology
Background:
- Myeloproliferative disorders (MPD) can affect platelet function.
- Assessing platelet aggregation is crucial for understanding MPD and treatment responses.
Purpose of the Study:
- To characterize platelet aggregation using multiple electrode aggregometry (MEA) in MPD patients.
- To evaluate MEA's utility in detecting platelet dysfunction and monitoring anti-platelet drug efficacy in MPD.
Main Methods:
- Compared platelet aggregation responses (ASPI, ADP, TRAP tests) in 55 MPD patients and 75 controls using hirudin-anticoagulated blood.
- Utilized multiple electrode aggregometry (MEA) for platelet function analysis.
Main Results:
- No statistically significant platelet dysfunction was observed in MPD patients compared to controls.
- Platelet and leukocyte counts were identified as significant factors influencing MEA results.
- Aspirin (ASA) and clopidogrel treatment significantly reduced ASPI and ADP test values, validating MEA for monitoring anti-platelet therapy.
Conclusions:
- MEA is a valid method for monitoring aspirin (ASA) and clopidogrel treatment in MPD patients and controls.
- Platelet and leukocyte counts are key factors affecting MEA aggregation tests.
- No functional platelet abnormalities were detected in the studied MPD patient cohort.
Related Concept Videos
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:18Structure and Function of Platelets
Platelets are continually replenished, circulating in the bloodstream for 9-12 days before being removed by phagocytes, primarily in the spleen. A microliter of circulating blood contains between 150,000 and 450,000 platelets, with...